Wall Street Analysts Are Neutral on Top Healthcare Picks


Analysts fell to the sidelines weighing in on and Regeneron (REGN) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Regeneron (REGN)

In a report issued on October 30, Cory Kasimov from J.P. Morgan maintained a Hold rating on Regeneron. The company’s shares closed last Wednesday at $470.09.

According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 22.2% and a 56.3% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $681.73 average price target, implying a 42.9% upside from current levels. In a report issued on November 5, Raymond James also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on REGN:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts